Literature DB >> 19509591

Surgical resection in the management of pulmonary metastatic disease of gestational trophoblastic neoplasia.

Yang Cao1, Yang Xiang, Fengzhi Feng, Xirun Wan, Xiuyu Yang.   

Abstract

The objective of this study was to evaluate the influence of surgical resection on survival outcome in patients with gestational trophoblastic neoplasia with pulmonary metastatic disease. Medical records of 62 patients with gestational trophoblastic neoplasia who underwent pulmonary lobectomy or limited resection were reviewed. The cases were divided into 3 groups, namely, the recurrent group (group A), the drug-resistant group (group B), and the group with satisfactory response to chemotherapy but with residual pulmonary lesion (group C). The proportion of high-risk patients was significantly lower in group C, whereas this group had a remarkable complete remission rate of 100% with no relapse recorded, and only 3 patients (12.0%) in this group had a positive histologic diagnosis. The complete remission rates of groups A and B were 88.9% and 78.6%, respectively, and the relapse rates were 14.3% and 15.0%, respectively. By comparing treatment failure cases with patients who achieved complete remission, factors that might affect the clinical outcome of pulmonary surgery were also analyzed. Patients who have received more than 4 regimens or 13 courses of preoperative chemotherapy seemed to have unfavorable prognosis (P < 0.05). Follow-ups could be carried out without surgical resection for patients with satisfactory response to chemotherapy but with residual pulmonary lesions. Pulmonary surgery is indicated when clinical evidence suggests that pulmonary metastatic disease causes relapse or drug-resistance and the lesions are relatively localized. However, surgery is not advisable for patients who received more than 4 regimens or 13 courses of preoperative chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509591     DOI: 10.1111/IGC.0b013e3181a3d014

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Primary pulmonary cancer colliding with metastatic choriocarcinoma.

Authors:  Zheng Wang; Jingwen Si; Jingwei Liu
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

2.  Doppler-based predictive model for methotrexate resistance in low-risk gestational trophoblastic neoplasia with myometrial invasion: prospective study of 147 patients.

Authors:  J Qin; S Zhang; L Poon; Z Pan; J Luo; N Yu; L Wang; X Wu; X Cheng; X Xie; Y Lu; W Lu
Journal:  Ultrasound Obstet Gynecol       Date:  2021-05       Impact factor: 7.299

Review 3.  [Progress of the diagnosis and treatment of pulmonary metastasis of gestational choriocarcinoma].

Authors:  Dongjie Ma; Zhiyong Zhang; Shanqing Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-10

4.  Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017.

Authors:  Yujia Kong; Liju Zong; Hongyan Cheng; Fang Jiang; Xirun Wan; Fengzhi Feng; Tong Ren; Jun Zhao; Junjun Yang; Yang Xiang
Journal:  Cancer Med       Date:  2020-02-05       Impact factor: 4.452

5.  Rare Case of a Young Female With Co-existent Hydatidiform Mole and Pulmonary Metastases: An Underrecognized Entity.

Authors:  Ravikanth Reddy
Journal:  Cureus       Date:  2021-12-07

6.  Thoracotomy in refractory gestational trophoblastic neoplasia with lung metastasis after normalization of serum beta human chorionic gonadotropin (β-hCG) with salvage chemotherapy.

Authors:  Fengzhi Feng; Huiying Hu; Lei Wu; Tong Ren; Xirun Wan; Yang Xiang
Journal:  Onco Targets Ther       Date:  2014-01-29       Impact factor: 4.147

7.  Thoracoscopic Surgery to Treat Lung Metastases from Refractory Choriocarcinoma.

Authors:  Luo Zhao; Yingzhi Qin; Dongjie Ma; Li Li; Zhijun Han; Shanqing Li; Hongsheng Liu
Journal:  Cancer Manag Res       Date:  2020-05-25       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.